Effects of Endothelial and Mesenchymal Stem Cells on Improving Myocardial Function in a Sheep Animal Model

Shahram Rabbani, PhD¹, Masoud Soleimani, PhD², Mohammad Sahebjam, MD¹, Mohammad Imani, PhD³, Seyed Mahdi Nassiri, DVSc⁴, Amir Atashi, PhD⁵, Morteza Daliri Joupari, PhD⁶, Ali Ghiaseddin, PhD², Mostafā Latifpour, PhD¹, Seyed Hossein Ahmadi Tafti, MD*¹

¹Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
²Tarbiat Modares University, Tehran, Iran.
³Iran Polymer and Petrochemical Institute, Tehran, Iran.
⁴Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
⁵Stem Cell and Tissue Engineering Research Center, Shahroud University of Medical Sciences, Shahroud, Iran.
⁶National Institute for Genetic Engineering and Biotechnology, Tehran, Iran.

Received 02 November 2016; Accepted 09 February 2017

Background: Myocardial infarction is the main cause of death worldwide. Angiogenesis, a promising new therapy for the treatment of diffuse coronary artery disease, shows a poor response to conventional revascularization techniques. This study focused on improving myocardial function using endothelial cells (ECs) and mesenchymal stem cells (MSCs) in a sheep animal model.

Methods: Acute myocardial infarction was induced in 18 sheep (12 treated cases and 6 controls). Autologous MSCs and ECs were injected in the infarcted area and the border zone. Two months after transplantation, echocardiography, electron microscopy, and immunohistochemistry were performed.

Results: Echocardiography in both MSC and EC groups revealed a significant improvement in the ejection fraction compared with the control group (p value < 0.05). Vascular density, estimated by antibodies against the von Willebrand factor and smooth muscle actin, increased in both study groups. The pattern of vascularity in the MSC and EC groups was diffused. The electron microscopic evaluation of the infracted areas revealed cardiomyocytes in variable stages of development in the border zone in both EC and MSC groups.

Conclusion: Both ECs and MSCs were able to promote angiogenesis and improve cardiac function. Presumably, MSCs differentiate into ECs and cause angiogenesis as it occurs for ECs.

J Teh Univ Heart Ctr 2017;12(2):65-71

This paper should be cited as: Rabbani S, Soleimani M, Sahebjam M, Imani M, Nassiri SM, Atashi A, Daliri Joupari M, Ghiaseddin A, Latifpour M, Ahmadi Tafti SH. Effects of Endothelial and Mesenchymal Stem Cells on Improving Myocardial Function in a Sheep Animal Model. J Teh Univ Heart Ctr 2017;12(2):65-71.

Keywords: Endothelial cells • Mesenchymal stem cell transplantation • Myocardial infarction • Sheep
Introduction

Cardiovascular diseases are the main cause of hospitalization and death globally. Myocardial infarction is one of the leading causes of death in both developing and developed countries.1 Myocardial infarction is characterized by significant irreversible loss of cardiomyocytes, leading to impaired ventricular function. When the heart’s blood flow is interrupted or reduced by a blockage in the coronary artery, cardiomyocytes will be necrotic and will be eventually replaced by scar tissue.2 Heart failure occurs at the end of pathological myocardial remodeling due to either ischemic or nonischemic cardiomyopathy.

The routine treatments for people suffering heart attack are balloon angioplasty and coronary artery bypass grafting surgery. However, conventional therapy for heart failure generally does not replace myocardial necrosis with new contractile tissue.3 Consequently, new therapeutic approaches have been investigated to decrease myocardial injury and formation of new vessels for ischemic area perfusion. Although heart transplantation is the last therapy option for severe heart failure, shortage of heart donors has limited the application of this therapy. This has led to the development of novel therapeutic approaches, including cellular cardiomyoplasty.4 Recently, cell therapy has been performed to prevent myocardial damage via angiogenesis. Overview of the trials indicates that this novel treatment could result in some improvements compared with conventional therapy.5

Cell transplantation is a promising treatment strategy for repairing ischemically damaged hearts.6,7 Over the past decade, various cell types have been proposed as potential useful candidates, including skeletal myoblasts, embryonic cells, hematopoietic cells, and mesenchymal stem cells (MSCs).8 Bone marrow contains several types of stem cells with distinct capability of generating cardiomyocytes. MSCs, multipotent stem cells that reside within the bone marrow microenvironment,9 can regenerate cardiac muscle by self-renewal and differentiation into cardiomyocytes.10 Although bone marrow-derived MSCs have been successfully used experimentally11 and clinically,12 bone marrow aspiration is a very painful procedure and mostly has been performed under spinal or general anesthesia.13

Angiogenesis is a promising new therapy currently under intense investigation. Formation of new vessels can confer better perfusion of the myocardium and subsequently prevent infarct area expansion.14 Therapeutic angiogenesis starts with the migration and proliferation of endothelial cells (ECs) as new vascular beds.15 It has been reported that endothelial progenitor cells release angiogenic factors like vascular endothelial growth factor and, therefore, augment the cardiac performance, probably by improving regional circulation.16 However, ECs are unable to differentiate into cardiomyocytes.17

Currently, there is limited information available regarding angiogenesis effects and ventricular function following EC transplantation into myocardial scar tissue.18 We hypothesized that MSCs and ECs can promote angiogenesis, one via differentiation into ECs and the other via propagation and proliferation. The objective of the current research project was to compare the effects of EC and MSC transplantation on improving myocardial function using a sheep model of myocardial infarction.

Methods

All the animal experiments were done in accordance with the National Institute of Health (NIH)’s guideline (Guide for the Care and Use of Laboratory Animals, NIH publication 8523, revised 1996).

The animals included in this study were 18 Iranian ewes (40 ± 5 kg). The animals were clinically healthy and had not been included in any previous experimental study. The animals were housed in standard cages under a protocol approved by the institutional Animal Care and Use Committee. All the animals were fed ad libitum with hay and sheep pellets and had free access to water. The animals were assigned to 3 groups: Group I (control, n = 6) underwent diagonal artery ligation with culture media, Group II (MSC, n = 6) underwent diagonal artery ligation with MSC transplantation, and Group III (EC, n = 6) underwent diagonal artery ligation with EC transplantation.

The sheep were anesthetized with intramuscular injections of xylazine (5 mg/kg). Following the iliac crest puncture, a 5–8 mL-sample of bone marrow was promptly aspirated with an 18-gauge needle into a 10-mL syringe containing heparin (3000 units/mL). Also, a piece of saphenous vein (about 5 cm) was harvested for cell culture. ECs, and bone marrow-derived mononuclear cells (BM-MNCs) were isolated according to a method described previously.19 Briefly, BM-MNCs and ECs were harvested using a Ficoll gradient centrifugation. Then, the cells were washed with phosphate-buffered saline (PBS), pelleted by centrifugation at 3000 rpm, and resuspended in 5–7 mL of the culture medium of Dulbecco’s modified Eagle’s medium (DMEM; Gibco, U.S.A.) supplemented with 20% fetal bovine serum (FBS; Gibco, U.S.A.). The cells were subsequently seeded into 25T culture flasks and incubated in humidified atmosphere at 37 °C with 95% air and 5% CO2. The medium was changed every 2 days. During the medium changes, non-adherent mononuclear and red blood cells were discarded. After about 5–7 days, the attached cells grew and developed colonies. The MSCs were passaged twice prior to detachment using trypsin-EDTA (Gibco, U.S.A.). The cells harvested at each passage were used for cell transplantation.

Experimental myocardial infarction in the sheep was performed according to the procedure described elsewhere.20 Briefly, the sheep were nil per os (NPO) 24 hours prior to

66
surgery. Anesthesia was induced with intravenous injections of 5 mg/kg of sodium thiopental and maintained with 2–3 vol% halothane in oxygen. The anesthetized animals were then orally intubated with a size 7.5 endotracheal tube and mechanically ventilated (Draeger Ventilog 3, Lubeck, Germany) with 100% O2, at a tidal volume of 10 mL/kg, and respiratory rate of 12–14/min. After sterile preparation and draping, a left lateral thoracotomy incision (15–20 cm in length) was made through the 4th left intercostal space. After the pericardium was opened, the coronary anatomy was inspected. A 6-0 Prolene™ suture was placed around the 2nd diagonal branch of the left anterior descending coronary artery at an approximately 40% distance from its base (Figure 1). Myocardial ischemia was confirmed by ventricular hypokinesis, cardiac tissue cyanosis, and electrocardiographic (ECG) ST-segment elevation.20 Thereafter, 200 µL of culture media (control group), 200 µL of culture media containing 27 × 10^6 MSCs (MSC group), and 200 µL of culture media containing 27 × 10^6 ECs (EC group) were injected into the border of the ischemic area at 4 sites after diagonal branch ligation in all the groups separately. Next, the thoracotomy incision was closed (muscles and skin with 2-0 Vicryl™ suture and pericardium with 5-0 Prolene™ suture). For arrhythmia prophylaxis, lidocaine was administered intravenously (2 mg/kg) as a loading bolus dose just before diagonal branch ligation and 15–20 minutes thereafter at 1 mg/kg.21 The animals were discharged from the intensive care unit 24 hours after surgery. All the surgical operations were performed without mortality or any major morbidity. The left ventricular ejection fractions (LVEFs) are presented in Table 1. The results of this study show that the EF was initially decreased 1 day after surgery in all the groups. However, 2 months after surgery, significant increases in the mean values of the EF were present in the animals that received MSC or EC transplantation (p value < 0.001 and p value = 0.003, respectively), compared to the control animal group. No statistically significant difference was present between the animals that received MSC transplantation and those that received EC transplantation (p value = 0.230).

Table 1. Pre- and post-operative myocardial ejection fraction (EF) in the sheep that received mesenchymal stem cell (MSC) or endothelial cell (EC) transplantation, compared to the control group

| Group | Preoperative EF (%) | Postoperative EF (%) |
|-------|---------------------|----------------------|
|       | 1 day               | 2 months             |
| Control | 70.33±4.08a**      | 50.17±8.54a          | 48.67±6.80a          |
| MSCs   | 70.67±6.41a        | 48.67±3.33a          | 65.33±4.08b          |
| ECs    | 69.17±7.03a        | 44.00±4.69a          | 62.00±4.86b          |
| Effect size | 2.99           | 3.59                 | 1.61                 |

*Data are presented as mean±SD
**Values with similar superscript letters (a & b) have statistically no significant differences.

Figure 2 and Figure 3 show the results of the immunohistochemical staining for vWF and SMA. The vWF-positive cells were counted in the infarcted area as well as in the border zone (Figure 2), and the SMA-positive cells were counted in the developing vasculature (Figure 3). The results of the counted vWF- or SMA-positive cells are presented in Table 2. The statistical analysis of the number of...
the vWF-positive cells revealed that capillary density in the infarcted area was significantly greater in the animals that received MSC or EC (p value < 0.001 and p value < 0.001, respectively) transplantation than in the control group. However, no significant difference was present between the MSC and EC groups (p value = 0.865).

Figure 2. Immunohistochemical staining for von Willebrand factor in the infarct area in the control group (a), in the animals that received mesenchymal stem cells (b) or endothelial cells (c). (Magnification 100X)

Figure 3. Immunohistochemical staining for smooth muscle actin in the control group (a), in the animals that received mesenchymal stem cells (b), and in the animals that received endothelial cells (c). (Magnification 100X)

The results of vascular density in the border zone were similar to those in the infarcted area. The differences between the control group and the MSC or EC groups were statistically significant (p value < 0.001). No significant difference was present between the MSC and EC groups (p value = 0.881). Furthermore, the number of SMA-positive arterioles was statistically higher in the MSC (p value =
0.023) and EC (p value = 0.006) groups than in the control animals. No statistically significant difference was noted between the MSC and EC groups (p value = 0.684).

In the electron microscopic studies of the infarcted areas, cardiomyocytes in variable stages of development were seen in the border zone in both MSC and EC groups (data not shown).

**Table 2. Vascular density as measured by the number of blood vessels using antibodies against von Willebrand factor (vWF) and smooth muscle actin (SMA) in the sheep 2 months after mesenchymal stem cell (MSC) or endothelial cell (EC) transplantation**

| Group       | Infarct Area | Border Zone | SMA          |
|-------------|--------------|-------------|--------------|
| Control     | 23.28±1.24** | 29.60±5.87* | 27.73±8.14*  |
| MSCs        | 60.91±20.50* | 79.45±18.72* | 103.59±66.16* |
| ECs         | 63.02±18.75* | 78.00±13.95* | 89.90±42.77* |
| Effect size | 2.99         | 3.59        | 1.61         |

aData are presented as mean number of vessels per high power field of microscope±SD

**Values with similar superscript letters (a & b) have statistically no significant differences.**

**Discussion**

Several animal studies have been performed using MSC transplantation after myocardial infarction and demonstrated positive effects on left ventricular (LV) function, reduction of the infarct size, and reduction of mortality rate. Shinji Tomita et al.22 in 1999 used autologous bone marrow cells transplanted into ventricular cryoinjured scar tissue. They differentiated these cells to cardiomyocytes and observed angiogenesis and improved cardiac function. Dai et al.23 showed that allogeneic MSC transplantation in the post-infarcted rat myocardium was able to transiently improve global LV function at 4 weeks possibly due to an early paracrine effect. In a canine chronic ischemia model, Silva et al.24 reported that MSC differentiation into endothelial and smooth muscle cells was able to increase vascularity and improve cardiac function. Grauss et al.25 used human MSCs in immunocompromised non-obese diabetic/susceptible insulin dependent (NOD/SCID) mice and showed improved LV function and limited LV remodeling. Miyahara et al.26 used monolayered MSC sheets in infarcted rat hearts. They observed undifferentiated cells, newly formed vasculature, and few cardiomyocytes in the engrafted sheet. The monolayered MSCs improved cardiac function in rats with myocardial infarction.

MSCs can be easily cultured and they can remain multipotent. Moreover, they are highly proliferative and can differentiate into many cell types, especially smooth muscle and ECs; however, they have limited potential to differentiate into cardiomyocytes.27 The differentiation of these cells is age-dependent and aged cells may show low expansion in vitro. Also, obtaining these cells requires bone marrow aspiration, which is an inconvenient method for the patients. Furthermore, these cells may have some side effects such as fibrosis and calcification.28 It has been shown that the transplantation of bone marrow-derived MSCs with and without co-culture with myocardial cells reduces the infarct size in ischemic rat hearts.29 Myocardial injection of human STRO-1 mesenchymal progenitors, in an athymic rat model of acute myocardial infarction, enhanced vascular density, induced neovascularization, and improved myocardial ejection fraction (EF).30

In contrast with MSCs, EC transplantation for improving myocardial function has been rarely employed. EC transplantation is less time-consuming and is a relatively cost-effective procedure. ECs can be easily obtained from a piece of vessel. Although these cells are also age-dependent, EC transplantation has no side effects. ECs never differentiate into bone or any other undesirable tissues. Following the injection of ECs, only angiogenesis and improved cardiac function via formation of new vessels are expected. In a rat model of cardiac injury, EC transplantation into a myocardial scar stimulated angiogenesis and increased regional perfusion in myocardial scar tissue without any positive effect on global function.18

Using autologous mature EC transplantation could become a useful alternative to other cell therapy. ECs induce a wide capillary network; however, their transplantation may not lead to sufficient functional vasculature formation. A reduced EF was found to be one of the major determinants of cardiac mortality. The results of our study showed that the transplantation of both MSCs and ECs was able to improve cardiac function and induce angiogenesis. MSCs can differentiate into ECs and hence prevent an increase in the ischemic area. Apropos the effect size (Table 1 and Table 2), as was expected, where the p values were significant, our study had a good power and where the p values were not significant, there was a small effect size.

The electron microscopic studies showed that the ECs had also differentiated into cardiomyocytes. This can prevent a drop in the EF via decreasing the infarcted area. The appearance of developing cardiomyocytes in the EC group can be at least partially due to a better perfusion of the heart and the presence of appropriate environment for the native stem cells to differentiate into cardiomyocytes.

In light of the results of this work, we can suggest the use of adult ECs instead of stem cells obtained from the very invasive method of bone marrow aspiration. Only a part of vein can be harvested to obtain adult ECs.

**Conclusion**

The results of this study demonstrated that EC transplantation, similar to MSC transplantation, was able to
improve cardiac function and angiogenesis. Further studies on the use of ECs for myocardial regeneration are required to arrive at a firm conclusion on the usefulness of these cells.

**Acknowledgments**

This study was financially supported by the Research Department of Tehran Heart Center. The authors would like to thank the faculty, researchers, and staff of Tehran Heart Center. We also acknowledge Dr. Mehrdad Ameri for reviewing this manuscript.

**References**

1. Mansour S, Roy DC, Lemiche B, Ouellet C, Stevens LM, Noisieux N. Stem cell therapy for the broken heart: mini-organ transplantation. Transplant Proc 2009;41:3353-3357.
2. Krijnen PA, Nijmeijer R, Meijer CJ, Visser CA, Hack CE, Nissen HW. Apoptosis in myocardial ischaemia and infarction. J Clin Pathol 2002;55:801-811.
3. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005;111:2837-2849.
4. Babu GG, Walker JM, Yellon DM, Hausenloy DJ. Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. Eur Heart J 2011;32:23-31.
5. Fisher SA, Zhang H, Doree C, Mathur A, Martin-Rendon E. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2015(9):CD006536.
6. Shabbir A, Zisa D, Suzuki G, Lee T. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am J Physiol Heart Circ Physiol 2009;296:H1888-1897.
7. Tse HF, Siu CW, Zhu SG, Songyan L, Zhang QY, Lai WH, Kwong YL, Nicholls J, Lau CP. Paracrine effects of direct intramyocardial implantation of bone marrow derived cells to enhance neovascularization in chronic ischaemic myocardium. Eur J Heart Fail 2007;9:747-53.
8. Wang F, Guan J. Cardiomyoplasty and cardiac tissue engineering for myocardial therapy. Adv Drug Deliv Rev 2010;62:784-97.
9. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshall DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
10. Ball SG, Shuttleworth AC, Kiely CM. Direct cell contact influences bone marrow mesenchymal stem cell fate. Int J Biochem Cell Biol 2004;36:714-727.
11. Makkar RR, Price MJ, Lill M, Frantzen M, Takizawa K, Klekis T, Zheng J, Kar S, McClean R, Miyamoto T, Bick-Forrester J, Fishbein MC, Shah PK, Forrester JS, Sharifi B, Chen PS, Qayyum M. Intramyocardial injection of allogenic bone marrow-derived mesenchymal stem cells without immunosuppression preserves cardiac function in a porcine model of myocardial infarction. J Cardiovasc Pharmacol Ther 2005;10:225-233.
12. Dill T, Schüchner V, Rolf A, Möllmann S, Thiele H, Tillmanns H, Assmus B, Dimmeler S, Zeiher AM, Hamm C. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy. Am Heart J 2009;157:541-547.
13. Premaratne GU, Ma LP, Fujita M, Lin X, Bollano E, Fu M. Stromal vascular fraction transplantation as an alternative therapy for ischemic heart failure: anti-inflammatory role. J Cardiothorac Surg 2011;6:43.
14. Furfani AP, Kalil RA, Castro I, Cañedo-Delgado A, Barra M, Prates PR, Sant’Anna RT, Nesralla IA. Effects of therapeutic angiogenesis with plasmid VEGF165 on ventricular function in a canine model of chronic myocardial infarction. Rev Bras Cir Cardiovasc 2009;24:143-149.
15. Payne TR, Oshima H, Okada M, Monnoi N, Tobita K, Keller BB, Peng H, Huard J. A relationship between vascular endothelial growth factor, angiogenesis, and cardiac repair after muscle stem cell transplantation into ischemic hearts. J Am Coll Cardiol 2007;50:1677-1684.
16. Schuh A, Liehn EA, Sasse A, Hristov M, Sobota R, Kelm M, Merx MW, Weber C. Transplantation of endothelial progenitor cells improves neovascularization and left ventricular function after myocardial infarction in a rat model. Basic Res Cardiol 2008;103:69-77.
17. Gruh I, Beilner J, Blomer U, Schmiedl A, Schmidt-Richter I, Kruse ML, Haverich A, Martin U. No evidence of transdifferentiation of human endothelial progenitor cells into cardiomyocytes after coculture with neonatal rat cardiomyocytes. Circulation 2006;113:1326-1334.
18. Kim EJ, Li RK, Weisel RD, Mickle DA, Jia QZ, Tomita S, Sakai T, Yau TM. Angiogenesis by endothelial cell transplantation. J Thorac Cardiovasc Surg 2001;122:963-971.
19. Gneccchi M, Melo LG. Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. Methods Mol Biol 2009;482:281-294.
20. Rabbani S, Ahmad H, Fayazzadeh E, Sahebjam M, Boroumand MA, Sotudeh M, Nassiri SM. Development of an ovine model of myocardial infarction. ANZ J Surg 2008;78:78-81.
21. Kim WG, Park JJ, Oh SI. Chronic heart failure model with sequential ligation of the homonymous artery and its diagonal branch in the sheep. ASAIO J 2001;47:667-672.
22. Tomita S, Li RK, Weisel RD, Mickle DA, Kim EJ, Sakai T, Jia QZ. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999;100(19 Suppl):II247-56.
23. Dai W, Hale SL, Martin BJ, Kuang QJ, Dow JS, Wold LE, Kloner RA. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation 2005;112:214-23.
24. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D, Coulter SC, Lin J, Ober J, Vaughn WK, Branco RV, Oliveira EM, He R, Geng YJ, Willerson JT, Perin EC. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 2005;111:150-156.
25. Grauss RW, van Tuyn J, Steendijk P, Winter EM, Pijnappels DA, Bogers H, Gittenberger-De Groot AC, van der Geest R, van der Laarse A, de Vries AA, Schalij MJ, Atsma DE. Forced myocardial expression enhances the therapeutic effect of human mesenchymal stem cells after transplantation in ischemic mouse hearts. Stem Cells 2008;26:1083-1093.
26. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Minakawa K, Hoshino K, Ishida H, Shimizu T, Kangawa K, Sano S, Okano T, Kitamura S, Mori H. Mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 2006;12:459-465.
27. Jogerst SJ, Hatzopoulos AK. Stem cell therapy for cardiac repair: benefits and barriers. Expert Rev Mol Med 2009;11:e20.
28. Yoon YS, Park JS, Tsubokawa T, Luedeman C, Losordo DW. Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation 2006;114:3068-3076.
29. Li XH, Fu YH, Liu ZY, Zhang GF, Dong GF, Lin QX, Yu XY. Efficacy comparison between transplanting microenvironmental induced and non-induced bone marrow mesenchymal stem cells in ischemic rat hearts. Zhonghua Xin Xue Guan Bing Za Zhi 2009;37:680-684.

30. Martens TP, See F, Schuster MD, Sondermeijer HP, Hefiti MM, Zannettino A, Gronthos S, Seki T, Itescu S. Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. Nat Clin Pract Cardiovasc Med 2006;3:S18-22.